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SUMMARY 30 
WĂŝŶŝƐĂƉƌĞǀĂůĞŶƚƐǇŵƉƚŽŵŽĨWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ?and is effectively treated by deep brain 31 
stimulation of the subthalamic nucleus (STN). However, the link between pain and the STN 32 
remains unclear. In the present work, we report that STN neurons exhibit complex tonic and 33 
phasic responses to noxious stimuli using in vivo electrophysiology in rats. We also show that 34 
nociception is altered following lesions of the STN, and characterize the role of the superior 35 
colliculus and the parabrachial nucleus in the transmission of nociceptive information to the 36 
STN, physiologically from both structures and anatomically in the case of the parabrachial 37 
nucleus. We show that STN nociceptive responses are abnormal in a rat model of PD, 38 
suggesting their dependence on the integrity of the nigrostriatal dopaminergic system. The 39 
STN-linked nociceptive network we reveal is likely to be of considerable clinical importance 40 
in neurological diseases involving a dysfunction of the basal ganglia. 41 
 42 
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INTRODUCTION 54 
Pain is highly prevalent in PĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ?W ?and includes primary symptoms assumed 55 
to originate from a dysfunction of the central nervous system. Patients describe bizarre and 56 
unexplained painful sensations such as painful burning, stabbing, aching, itching or tingling 57 
sensations, predominating on the more affected side (Schestatsky et al., 2007). These 58 
symptoms are not directly related to the pain caused by the motor symptoms (Ha and 59 
Jankovic, 2011). Sensitivity to noxious stimulation is also increased in patients with PD, with 60 
or without pain symptoms (Berardelli et al., 2012; Brefel-Courbon et al., 2013; Tinazzi et al., 61 
2008), and their nociceptive threshold is altered (Chudler and Dong, 1995; Conte et al., 2013; 62 
Djaldetti et al., 2004). Although it is well known that PD affects the basal ganglia, there is to 63 
date no clear description of a link between the basal ganglia and the cerebral network 64 
involved in pain. Interestingly, deep brain stimulation of the subthalamic nucleus (STN-DBS) 65 
in PD, a valuable and effective therapeutic technique for motor symptoms (Krack et al., 66 
2003; Limousin et al., 1998), has also been shown to reduce pain (Cury et al., 2014; Hanagasi 67 
et al., 2010; Kim et al., 2008; Klingelhoefer et al., 2014). In contrast, the effects of dopamine 68 
replacement therapy on the pain symptoms in PD are controversial, with some 69 
investigations reporting an improvement, no effect or an aggravation of pain symptoms or 70 
nociceptive thresholds (Conte et al., 2013, Dellapina et al., 2011). These variable results of 71 
dopamine replacement therapy indicate a role for other systems in the pain symptoms 72 
observed in PD. Importantly in the present context, it has been demonstrated that pain relief 73 
following STN DBS is superior to that following dopaminergic treatment, further positioning 74 
STN as a crucial structure in pain symptoms in PD and their relief (Sürücü et al., 2013).  75 
The mechanism by which STN-DBS improves pain in PD patients remains unclear, which 76 
raises a fundamental question about the link between the subthalamic nucleus (STN) and 77 
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pain. Preliminary evidence suggests that noxious stimulation can modulate background 78 
activity in the STN, at least in the parkinsonian brain (Belasen et al., 2016; Heise et al., 2008). 79 
As a consequence, the STN could be linked to a nociceptive network involved in the 80 
perception of noxious stimuli, although this has yet to be fully explored. Despite the classical 81 
description of a sensory territory in the STN (Alexander et al. 1986) and the functional 82 
impact that STN sensory responses could have on the basal ganglia (Baunez et al., 2011), 83 
there is a paucity of information in the literature regarding the type of sensory stimuli 84 
activating this structure and the afferent sensory source(s) (Coizet et al., 2009; Hammond et 85 
al., 1978; Matsumura et al., 1992). Two major subcortical central targets for ascending 86 
nociceptive information from the spinal cord are potential relays for nociceptive information 87 
to the STN: the superior colliculus (SC) and the parabrachial nucleus (PBN) (Hylden et al., 88 
1989; Craig, 1995; Klop et al., 2005; McHaffie et al., 1989). 89 
We have shown that the SC, a highly conserved but evolutionarily ancient subcortical multi-90 
sensory structure, directly projects to the STN and is the primary, if not exclusive source of 91 
visual input to the STN (Coizet et al., 2009; Tokuno et al., 1994). This projection shows that 92 
subcortical hyper-direct pathways exist between brainstem sensorimotor structures and the 93 
STN which predate, from an evolutionary perspective, those from the cortex thus reinforcing 94 
the position of the STN as a critical input structure processing short latency visual signals in 95 
the basal ganglia (Baunez et al., 2011). The substantia nigra pars compacta (SNc) is also on 96 
the input side of the basal ganglia and we have shown that SNc receives nociceptive-related 97 
afferents from the PBN (Coizet et al., 2010), raising the possibility that the STN may also 98 
receive such inputs.  99 
It is interesting to note that the STN is well known to heavily project to basal ganglia output 100 
structures such as the substantia nigra pars reticulata (SNr) (Alexander et al., 1986; Gurney 101 
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et al., 2001), which in turn projects to the SC and PBN (Schneider, 1986; Deniau and 102 
Chevalier, 1992), linking the STN, SNr and SC/PBN anatomically. With the STN in a position to 103 
modulate a nociceptive network involving the SC/PBN, the elevated activity in the STN in 104 
parkinsonism (Bergman et al., 1994; Albin et al., 1995) could underlie some unexplained pain 105 
symptoms in this disease, with STN-DBS acting (at least in part) locally to achieve its 106 
analgesic effects. Nociceptive processing in the STN would also be consistent with the 107 
ŶƵĐůĞƵƐ ?Ɛ ƌŽůĞ ĂƐ ƉĂƌƚ ŽĨ ďƌĂŝŶ ?Ɛ ŝŶƚĞƌƌƵƉƚ ĐŝƌĐƵŝƚƌǇ (Jahanshahi et al., 2015), terminating 108 
behaviors that achieve negative outcomes, of which pain is a clear example. 109 
 110 
Therefore, the main objective of the present work was to characterize the link between STN 111 
and nociception, answering the following questions: 112 
-  Does the STN process nociceptive information? We explored the possibility that noxious 113 
stimulation could induce nociceptive responses in the rat STN with in vivo electrophysiology. 114 
- Is the STN linked to a nociceptive network? We tested the potential role of the SC and PBN 115 
in the transmission of nociceptive information to the STN, both physiologically and in the 116 
case of the PBN, anatomically. 117 
- Can manipulation of the integrity of the STN change nociceptive responses measured 118 
behaviorally? We tested STN lesioned and sham operated rats using a hot plate test.  119 
- Finally, to examine the hypothesis that STN dysfunction could underlie some pain 120 
symptoms observed in PD, we evaluated if STN nociceptive responses were abnormal in a rat 121 
model of PD.  122 
We present convergent evidence that the STN is functionally linked to a nociceptive network 123 
and that STN nociceptive responses are affected in parkinsonism. The objectives above are 124 
summarized in figure 1.  125 
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 126 
RESULTS 127 
Nociceptive responses in STN 128 
STN neurons: A total of 98 cells were recorded across the STN (Figure 2A). The STN neurons 129 
sampled in the present study were characterized by a triphasic action potential in majority of 130 
cases (n = 88, mean duration = 2.1 ± 0.06 ms), the remaining cells having a biphasic action 131 
potential (n = 10, mean duration 1.58 ± 0.12 ms) (Figure 2B). The STN cells had a mean 132 
baseline firing rate of 7.39 Hz (± 0.53 Hz) and exhibited various spontaneous patterns of 133 
activity such as an irregular pattern (n = 42, 43 %), a regular pattern (n = 26, 27 %) and a 134 
bursting pattern (n = 20, 20 %) (Figure 2C). The remaining cells (n = 10, 10 %) exhibited a 135 
mixture of these features. These electrophysiological characteristics are concordant with 136 
those reported elsewhere in the literature in anesthetized rats (Hassani et al., 1996; Kreiss et 137 
al., 1996; Hamani et al., 2004).  138 
 139 
Phasic response (Figure 3A): Following noxious stimulation performed on the contralateral 140 
hindpaw (120, 0.5 Hz), 19 STN cells remained unresponsive (19 %) while 79 STN neurons (81 141 
%) exhibited a phasic response to the footshock with several patterns of response: 142 
 143 
I. Monophasic excitation (n = 42): The response consisted of a monophasic excitation. This 144 
type of response could be subdivided into three categories according to their latencies and 145 
durations:  146 
1) Monophasic short/long (n = 20, Figure 3Aa): The cells exhibited a short latency, long 147 
duration excitation;  148 
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2) Monophasic short/short (n = 17, Figure 3Ab): The cells exhibited a short latency, 149 
short duration excitation;  150 
II. Biphasic +/+ (n = 22, Figure 3Ac): The cells had an initial short-latency, short duration 151 
excitation followed by a longer latency and longer duration excitation; 152 
III. Biphasic +/- (n = 10, Figure 3Ad): The response in these cells had two phases, a short 153 
latency, short duration excitation followed by an inhibition. 154 
IV. Triphasic +/-/+ (n = 5, Figure 3Ae): The response was characterized by an initial short 155 
latency, short duration excitation, then an inhibition or a marked reduction in firing rate 156 
followed by third late latency and long lasting excitation. 157 
The remaining phasic responses could not be classified this way (n = 5). 158 
The details of the latencies and durations of each response types can be found in the table 1 159 
below: 160 
RESPONSE TYPES 
PHASE 1 PHASE 2 PHASE 3 
LATENCY DURATION LATENCY DURATION LATENCY DURATION 
I. 
1. 
37,80 ± 
3,15 ms 
338.40 ± 
49.79 ms 
/ / / / 
2. 
20.18 ± 
3.15 ms 
34.47 ± 
3.92 ms 
/ / / / 
II. 
20.00 ± 
3.02 ms 
35.00 ± 
3.86 ms 
97.00 ± 
6.97 ms 
269.00 ± 
40.05 ms 
/ / 
III. 
23.00 ± 
4.61 ms 
69.00 ± 
19.59 ms 
133.70 ± 
32.76 ms 
176.70 ± 
3.83 ms 
/ / 
IV. 
16.4 ± 
4.57 ms 
46.4 ± 
7.90 ms 
101.2 ± 
18.56 ms 
28.2 ± 
5.27 ms 
227.6 ± 
43.53 ms 
216.8 ± 69.3 
ms 
 161 
A significantly larger number of non-responding cells were located in the caudal portion of 162 
STN (ʖ ?A? ? ? ? ? ?df = 2, p < 0.05, Figure 2A). Of the 24 cells activated by noxious stimulation 163 
which were tested for multi-modal responses, only three exhibited an excitation to non-164 
noxious somatosensory stimulation (light brush), hence the majority were nociceptive only 165 
cells. 166 
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 167 
Baseline firing rate (Figure 3B): The introduction of noxious stimulation induced a 168 
statistically significant increase in STN baseline firing rate (Wilcoxon test: W[97] = -1199 ; p = 169 
0.05 ; mean ± SEM: no noxious stimulation: 7.13 ± 0.51 Hz vs noxious stimulation: 7.78 ± 170 
0.52 Hz). However, we could clearly observe some cells decreasing their baseline firing rate 171 
when the footshock was delivered (figure 3B). We therefore performed an individual 172 
analysis on each of the 98 STN cells, whether responding to the noxious stimulation of not, 173 
to test if the change of their baseline firing rate after the introduction of the stimulation was 174 
statistically robust (Wilcoxon test, p < 0.05), and if so, in which direction the change took 175 
place. We identified 39 (40 %) and 17 (18 %) cells showing a siŐŶŝĨŝĐĂŶƚŝŶĐƌĞĂƐĞ ? “ƵƉ ?ŐƌŽƵƉ ?176 
ĂŶĚĚĞĐƌĞĂƐĞ ? “ĚŽǁŶ ?ŐƌŽƵƉ ?ŽĨƚŚĞŝƌďĂƐĞůŝŶĞĨŝƌŝŶŐƌĂƚĞǁŝƚŚƚŚĞƐƚŝŵƵůĂƚŝŽŶ ?ƌĞƐƉĞĐƚŝǀĞůǇ177 
ĂŶĚŶŽƐŝŐŶŝĨŝĐĂŶƚĐŚĂŶŐĞĨŽƌƚŚĞƌĞŵĂŝŶŝŶŐ ? ?ĐĞůůƐ ? ? ?A  ? “ŶŽĐŚĂŶŐĞ ?ŐƌŽƵƉ ? ?ŽŶƚŝŶŐĞŶĐǇ178 
analysis did not reveal a specific topography of their location within STN, or link to their 179 
action potential shape, or to the presence or absence of a phasic response. Once grouped 180 
ƚŽŐĞƚŚĞƌ ŝŶ ƚĞƌŵƐ ŽĨ ĚŝƌĞĐƚŝŽŶ ? ƚŚĞ  “ƵƉ ? ĂŶĚ  “ĚŽǁŶ ? ŐƌŽƵƉƐ ďŽƚŚ ĞǆŚŝďŝƚĞĚ Ă ƐƚĂƚŝƐƚŝĐĂůůǇ181 
significant change in their baseline firing rate (up: Wilcoxon test: W[38] = -780, p < 0.001; 182 
mean ± SEM: no noxious stimulation: 6.31 ± 0.83 Hz vs noxious stimulation: 9.09 ± 0.94 Hz; 183 
down: Wilcoxon test: W[16] = 153, p < 0.001; mean ± SEM: no noxious stimulation: 9.55. ± 184 
1.43 Hz vs noxious stimulation: 7.08 ± 1.26 Hz), ƵŶůŝŬĞƚŚĞ “ŶŽĐŚĂŶŐĞ ?ŐƌŽƵƉ (Wilcoxon test: 185 
W[41] = 245, p = 0.1272; mean ± SEM: no noxious stimulation: 6.92 ± 0.65 Hz vs noxious 186 
stimulation: 6.85 ± 0.67 Hz). Interestingly, the spontaneous firing rate of STN cells from the 187 
 “ĚŽǁŶ ? ŐƌŽƵƉ ŚĂĚ Ă ƐŝŐŶŝĨŝĐĂŶƚůǇ ŚŝŐŚĞƌ ĨŝƌŝŶŐ ƌĂƚĞ ƚŚĂŶ ƚŚĞ  “ƵƉ ? ĂŶĚ  “ŶŽ ĐŚĂŶŐĞ ? ŐƌŽƵƉƐ188 
during the control period (Mann-tŚŝƚŶĞǇƚĞƐƚ PhA? ? ? ? ?ƉAM ? ? ? ? ?ŵĞĂŶA?^D P “ƵƉ ? P ? ? ? ?A?189 
 ? ? ? ?,ǌǀƐ “ĚŽǁŶ ? P ? ? ? ?A? ? ? ? ?,ǌ ?hA? ? ? ? ?ƉA? ? ? ? ? ?ŵĞĂŶA?^D P “ŶŽĐŚĂŶŐĞ ? P ? ? ? ? ?A? ? ? ? ?190 
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,ǌ ǀƐ  “ĚŽǁŶ ? P  ? ? ? ? A?  ? ? ? ? ,ǌ ? ? ǁŚŝůĞ ƚŚĞ  “ƵƉ ? ĂŶĚ  “ŶŽ ĐŚĂŶŐĞ ? ŐƌŽƵƉƐ ĚŝĚ ŶŽƚ ĚŝĨĨĞƌ191 
significantly. This suggests the presence of a separate population of STN neurons with a 192 
higher firing rate. 193 
 194 
STN and nociceptive responses: Is nociceptive information in the STN functionally 195 
relevant? 196 
To evaluate the involvement of STN in nociceptive responses, we tested nociceptive 197 
responses in STN lesioned and sham operated rats behaviorally using a hot plate test. The 198 
lesions were positioned within specific sub regions of the STN, sparing the surrounding 199 
structures such as the zona incerta or the hypothalamus located above and medial to the 200 
STN, respectively. The bi-lateral STN lesions were localized in the posterior half (n = 6) or 201 
anterior/central (n = 6) parts of this structure, covering from 8 to 34 % of the total surface of 202 
both bilateral STN (mean ± SEM: 20 ± 2.4 %) (figure 4). 203 
These partial and highly localized STN lesions affected the nociceptive responses of the rats. 204 
Analysis showed a significant increase of the latency to produce the first sign of discomfort 205 
in the hot plate in the STN lesioned group compared to the sham group (mean ± SEM: 206 
control = 10.81 ± 0.83 seconds; STN lesioned = 14.35 ± 0.9 seconds, p < 0.05). 207 
 208 
Where does nociceptive information in the STN come from? 209 
Nociceptive responses in afferent structures: SC and PBN: Footshocks produced short 210 
latency, short duration excitatory responses in the SC and PBN (table 2). PBN nociceptive 211 
responses were smaller in magnitude and amplitude than those in SC. Footshocks did not 212 
change the spontaneous baseline firing rate in the SC or the PBN (SC: t[7] = 1.218 ; p = 0.13; 213 
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PBN: W = 8 ; number of pairs = 11; p = 0.38). The latencies of SC and PBN responses to the 214 
stimulation were both significantly shorter than those of the STN (SC-STN: t[15] = 2.88 ; p < 215 
0.001 ; mean ± SEM: SC: 9 ± 0.8 ms vs STN: 25.33 ± 5.27 ms; PBN-STN: t[22] = 3.34 ; p < 0.01 ; 216 
mean ± SEM: PBN: 11.55 ± 1.35 ms vs STN: 24.54 ± 3.13 ms). Given that the response to 217 
noxious stimulation in SC and PBN occurs before the STN, both structures could be part of 218 
the nociceptive afferent network directed at the STN. 219 
 220 
Effect of SC or PBN inhibition on STN nociceptive responses: To test the possibility that the 221 
SC or PBN transmits nociceptive signals to the STN, we pharmacologically inhibited their 222 
neuronal activity with muscimol, a GABAA agonist, and evaluated the effect of their 223 
temporary inactivation on STN nociceptive responses. Simultaneous recordings were made 224 
from SC (multi-unit) and STN (single unit) neurons (n = 9) or from PBN (multi-unit) and STN 225 
(single unit) neurons (n = 13) before and after the delivery of noxious footshock. 226 
 227 
Muscimol in the SC (table 2): The injection of muscimol adjacent to the SC electrode 228 
decreased the tonic activity in this structure (t[7] = 4.31 ; p < 0.001) and abolished the phasic 229 
responses altogether in three cases. In the remaining cases, the muscimol produced a 230 
significant reduction of the magnitude (t[4] = 5.49; p < 0.01), maximum amplitude (t[4] = 231 
3.18 ; p < 0.05), and a trend towards the duration of the response (t[4] = 1.74, p = 0.08), but 232 
did not affect the latency (p = 0.19). The depression of the SC neuronal activity by muscimol 233 
abolished STN nociceptive response in one case (1/9), and significantly reduced the duration 234 
of STN nociceptive responses in the remaining cases (t[7] = 3.27 ; p < 0.05), with a trend 235 
towards a decrease in magnitude, the difference being close to reaching the statistical 236 
11 
 
threshold (t[7] = 2.31 ; p = 0.054). The remaining parameters of the response and the 237 
baseline firing rate of STN cells were not statistically different to the pre-drug period. 238 
Muscimol in the PBN (table 2): The injection of muscimol adjacent to the PBN electrode 239 
significantly decreased tonic activity of this structure (t[10] = 2.59; p < 0.05) and abolished 240 
altogether the phasic nociceptive responses in the PBN in two cases. In the remaining cases, 241 
the injection of muscimol increased the latencies (t[8] = 3.12, p < 0.01) and produced a 242 
significant reduction of the duration of the response (t[8] = 3.44, p < 0.01), the magnitude 243 
(t[8] = 2.88; p < 0.01); and maximum amplitude (t[8] = 3.91; p < 0.01). Unlike the SC, this 244 
general depression of PBN neuronal activity by muscimol completely abolished nociceptive 245 
phasic responses in five STN cells (5/13, Figure 5) and significantly reduced numerous 246 
parameters of the remaining STN responses to the stimulation, such as the duration 247 
(Wilcoxon test: W = 31, number of pairs = 8, p < 0.05), magnitude (t[7] = 4.25 ; p < 0.01) and 248 
maximum amplitude (t[7] = 3.21, p < 0.01). Neither the latency (t[7] = 0.04, p = 0.48, ns) nor 249 
the baseline firing rate (t[12] = 0.19, p = 0.42, ns) were significantly affected by the injection 250 
of muscimol in PBN. 251 
 252 
These results show that PBN pharmacological blockade with muscimol is more effective at 253 
reducing STN phasic nociceptive responses. 254 
 255 
Effect of SC or PBN lesions on STN nociceptive responses: Suppression of SC activity by 256 
muscimol only had a small influence on STN phasic nociceptive responses unlike PBN 257 
inactivation. However, while the technique of micro-injection offers a temporary inactivation 258 
with a possibility of recovery, the comparison of its effects on STN nociceptive responses 259 
versus those following PBN injections could be affected by the fact that muscimol was less 260 
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effective at reducing SC phasic responses than those in the PBN, and by the difficulty of 261 
evaluating the spread of the injection in the SC and PBN. Therefore, we tested the effect of 262 
ipsilateral ibotenic acid lesions of the lateral part of SC or PBN, on STN phasic nociceptive 263 
responses. 264 
 265 
SC lesion: In all cases (n = 5), the lesion included the lateral SC and extended, in some cases, 266 
to the adjacent superficial and/or deep layers of this structure (Figure 6A and B). A total of 267 
28 STN cells were recorded in lesioned animals before and after noxious footshocks. Of 268 
these cells, 27 (94 %) still responded to the noxious stimulation. Analysis of the proportion of 269 
responding and non-responding cells between the control and SC lesioned rats showed a 270 
significant difference between both groups (ʖ ? = 2.98, df = 1, p < 0.05), with a larger 271 
proportion of responding cells in SC-lesioned rats compared to control animals (94 % vs 81 272 
%), and hence a facilitation of the occurrence of the STN nociceptive responses after the 273 
removal of the lateral SC.  274 
 275 
Analysis of the nociceptive-induced phasic responses in STN showed a close to significant 276 
reduction of the duration (Mann-Whitney, U = 85, p = 0.06), which is consistent with the 277 
reduction of duration observed previously after the injection of muscimol in SC. A plot of the 278 
distribution of STN responses according to their latency and duration in control and SC 279 
lesioned animals shows that this statistical tendency could be due to the loss of the longer 280 
lasting nociceptive responses in SC lesioned animals (Figure 6C, dotted line box). This is 281 
supported by the observation of an increased proportion of short latency/short duration 282 
response types and a decrease in the proportion of long lasting responses (Figure 6D). The 283 
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other parameters of the response did not differ significantly and the firing rate was 284 
statistically unaffected. 285 
 286 
PBN lesion: The injection of ibotenic acid in the PBN induced a near total lesion of this 287 
structure in one case, extending over 87 % of the PBN. This lesion also affected a small part 288 
of the caudal pedunculopontine nucleus. In the remaining cases, the lesion was only partial 289 
and affected between 30 to 60 % of this nucleus (Figure 7A and B). 290 
A total of 30 STN cells were recorded in PBN lesioned rats before and after noxious 291 
footshocks. Although the lesion did not cover the entire PBN, the proportion of responding 292 
cells in the STN was significantly reduced, with 15 cells (50 %) still responding to the noxious 293 
stimulation while the other 15 (50 %) did not respond. Analysis of the proportion of 294 
responding and non-responding cells between the control and PBN lesion rats showed a 295 
significant difference between both groups (ʖ ? = 11.03, df = 1, p < 0.001), with a larger 296 
proportion of non-responding cells in PBN lesioned rats compared to control animals (50 % 297 
vs 19 %), representing a significant suppression of STN nociceptive responses after the 298 
removal of the PBN. Analysis of the nociceptive-induced phasic responses in the responding 299 
STN cells showed a significant reduction of response duration (Mann-Whitney, U = 378, p = 300 
0.05), which is consistent with the reduction of duration previously observed after the 301 
injection of muscimol in PBN. However, unlike the pharmacological blockade, the magnitude 302 
and maximum amplitude of the responses were not affected. As expected, the latency and 303 
the baseline firing rates were not statistically different between PBN lesioned and control 304 
rats. 305 
A plot of the distribution of STN nociceptive responses according to their latency and 306 
duration in control and PBN lesioned animals shows that most types of responses described 307 
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in control rats disappeared. A cluster of responding cells with short latencies and durations 308 
remained (Figure 7C and D). 309 
 310 
Anatomical link between the PBN and the STN: Our electrophysiological experiments 311 
suggest that the PBN acts as a critical source of nociceptive input to the STN and the SC as a 312 
critical modulator of those responses. While the connection between the SC and the STN has 313 
been previously characterized (Coizet et al. 2009; Tokuno et al., 1994), the functional link 314 
between the PBN and the STN was puzzling as a previous neuroanatomical study 315 
characterizing afferent connections of the STN reported the absence of labeled terminals 316 
and fibers in the STN following the injection of an anterograde tracer in the parabrachial 317 
complex (Canteras et al., 1990). However, the characterization of PBN efferent connections 318 
has often focused on the amygdala or the hypothalamus, but a close examination of PBN-319 
related fiber pathways, especially to the amygdala, indicates that those fibers are travelling 320 
close to (Saper et al., 1980: figure 4F) or even partly within the STN (e.g. Bernard et al., 1989: 321 
figure 2J; Sarhan et al., 2005: Figure 9B3). Therefore, to better understand the anatomical 322 
basis of our electrophysiological data, we re-evaluated the parabrachio-subthalamic 323 
pathway using combination of anterograde and retrograde tract-tracing techniques.  324 
 325 
Anterograde tract-tracing: Injections of the anterograde tracers Phaseolus Vulgaris 326 
leucoagglutinin (PHA-l, n = 4) or biotinylated dextran amine (BDA, n = 4) into the PBN 327 
revealed a robust direct projection to the ipsilateral STN and a less substantial projection to 328 
the contralateral STN. The ipsilateral ascending fibers leave the PBN in an antero-dorsal 329 
direction and pass above and through the dorso-caudal pedunculopontine tegmental 330 
nucleus (Figure 8). There, they split into three large pathways (Figure 8A), a PBN - SC 331 
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(intermediate and deep layers), a PBN - thalamic and a PBN  W nigral ventral projection. PBN 332 
labeled axons traveling to the STN are a rostral extension of the pathway we have previously 333 
described (Coizet et al., 2010) from the PBN to the dopaminergic neurons in the ventral 334 
midbrain, the parabrachio-nigral pathway. A substantial number of fibers continue further 335 
forward to the amygdala and the cortex (Figure 8A). This parabrachio-subthalamic pathway 336 
originates in the lateral and medial PBN (lPBN and mPBN respectively). Thus, injections of 337 
either PHA-l or BDA centered preferentially on the lPBN or the mPBN were both associated 338 
with numerous labeled axons and terminals, which were differentially distributed within sub 339 
regions of the STN. PBN fibers and terminals were largely seen in a dorsal sheet that 340 
extended across the entire mediolateral axis of the STN (Figure 8B and C). Moving rostrally, 341 
they further spread across the dorsoventral area of the STN. Many anterogradely labeled 342 
boutons were located in the vicinity of labeled fibers (Figure 8B and C). 343 
 344 
Retrograde track tracing: To identify the regional distribution and morphology of the 345 
parabrachio-subthalamic projection neurons, we injected small quantities of the retrograde 346 
tracers Fluorogold (n = 4) or Cholera toxin subunit B (CTB, n = 2) in the STN. The projection to 347 
the STN exhibited little topography. Retrogradely labeled neurons were found in all 348 
subnuclei of both the ipsilateral and contralateral PBN, and also within the fibers of the 349 
superior cerebellar peduncle (cp) (Figure 9A and B). The density of the labeled cells was 350 
however significantly larger on the ipsilateral side, as confirmed by a three factor (Side: 351 
ipsilateral/contralateral; Level: AP 8.8/AP 9.3/AP 9.8; Subdivisions: Lateral/medial/cp) 352 
repeated-measures ANOVA (Side factor: F = 9.33, df = 1, p < 0.05) and varied within the PBN 353 
according to the AP level (interaction between the level and the subdivisions, F = 4.10, df = 4, 354 
p < 0.05). The density of the cells increased in the lateral PBN when moving rostrally and the 355 
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majority of the cells in mPBN were located in the posterior PBN. PBN neurons retrogradelly 356 
labeled by STN injections are small to medium sized (mean ± SEM: 229.25 ± 8.21 µm
2
, range 357 
from 102.1 to 681.10; n=184) with a majority of round (59 %) and bipolar (35 %) soma and 358 
some multipolar cell bodies (6 %) (Figure 9C).  359 
 360 
STN nociceptive responses in ĂƌĂƚŵŽĚĞůŽĨWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ 361 
In a classical rat model of PD induced by an injection of 6-hydroxydopamine (6-OHDA), a 362 
neurotoxin targeting dopaminergic neurons (DA), in the SNc, we tested whether STN 363 
nociceptive responses were dysfunctional. 364 
TH immunohistochemistry was used to assess the extent of the dopamine denervation 365 
induced by 6-OHDA in the DA lesioned rats. TH-labeled neurons on the lesioned side were 366 
reduced to an average of 6.13 ± 0.71 % (mean ± SEM) of those on the unlesioned side, with 367 
the remaining neurons located in the medial part of the SNc. The reduced number of 368 
dopaminergic cells led to an average decrease of 65.22 ± 2.08 % in the dopaminergic 369 
innervation of the striatum.  370 
A total of 34 and 43 cells were recorded in control and DA lesioned rats, respectively. As 371 
expected in a model of PD, STN cells had a significantly higher firing rate in DA lesioned rats 372 
compared to controls (mean ± SEM: control = 8.00 ± 1.04 ms; DA lesioned = 12.96 ± 2.02 ms, 373 
p < 0.05, figure 3A). STN responses to nociceptive stimulation were abnormal in the DA 374 
lesioned group. Analysis revealed that STN cells in PD rats exhibited significantly longer 375 
responses (mean ± SEM: control = 84.39 ± 16.75 ms; DA lesioned = 175.38 ± 39.85 ms, p < 376 
0.05) with a greater amplitude (mean ± SEM: control = 27.81 ± 3.58 ms; DA lesioned = 40.88 377 
± 5.91 ms, p < 0.05, figure 3C) and magnitude (mean ± SEM: control = 8.13 ± 1.38 ms; DA 378 
lesioned = 13.11 ± 2.47 ms, p < 0.05) compared to the sham control animals. The proportion 379 
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of cells exhibiting the three levels of STN baseline firing rate with the introduction of the 380 
stimulation (up, down or no change) was not altered in the PD rat groups (ʖ ? A?0.32; p = 381 
0.85). Therefore, STN phasic nociceptive responses in PD rats were exacerbated, while the 382 
tonic modulation of the firing rate was preserved. 383 
 384 
DISCUSSION 385 
The present study demonstrated for the first time that a large majority of STN neurons 386 
exhibit various mono- or multi- phasic responses to noxious stimulation, consistent with the 387 
hypothesis that one of the functions of the STN is to interrupt behavior when appropriate 388 
(Jahanshahi et al., 2015), in this case to select a more appropriate action to try to relieve the 389 
noxious sensation. STN nociceptive responses mainly had a short latency (~ 20  W 40 ms) and 390 
could be recorded all over the structure. We have shown that most of responsive cells are 391 
nociceptive specific, as only few of them respond to non-noxious somatosensory stimulation 392 
as well. In addition, we found that we could differentiate three types of STN neurons, which 393 
either showed an increase, a decrease or no change of their baseline firing rate with the 394 
introduction of the noxious ƐƚŝŵƵůĂƚŝŽŶ ?dŚĞƐƉŽŶƚĂŶĞŽƵƐĨŝƌŝŶŐƌĂƚĞŽĨ^dE “ĚŽǁŶ ?ĐĞůůƐǁĂƐ395 
significantly higher compared to the two other groups, suggesting the possibility of a 396 
separate group of cells. Furthermore, we have shown that STN responses to nociceptive 397 
stimuli were abnormal in a rat model of PD, suggesting that the nociceptive responses 398 
recorded in STN depends on the integrity of the nigrostriatal DA system.  399 
 400 
When determining the afferent source of nociception-related influence on STN activity we 401 
have revealed a crucial role for two brainstem structures, the PBN and the SC, by 402 
demonstrating the effects of their inactivation on nociceptive responses in the STN and also 403 
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by highlighting the existence of an anatomical direct pathway from the PBN to the STN. This 404 
parabrachio-subthalamic projection represents a second example of a subcortical 405 
hyperdirect pathway to the STN from a sensori-motor structure, in addition to the tecto-406 
subthalamic pathway previously described (Coizet et al., 2009; Tokuno et al., 1994). Finally, 407 
we have shown that these anatomico-electrophysiological findings translate into a functional 408 
role for the STN in mediating nociception, in that nociceptive behavioral responses were 409 
affected by lesions of the STN. However, a note of caution required since we used only male 410 
rats, and thus care should be taken in extrapolating our results to females. 411 
 412 
Using noxious electrical stimulation of the hindpaw allowed us to precisely record the timing 413 
of responses in our structures of interest with controlled parameters of stimulation. It is 414 
interesting to note that the majority of STN nociceptive responses had short latencies 415 
(76/79) and were monophasic (40/79), which is similar in proportion to the pattern of STN 416 
responses following visual stimulation (Coizet et al., 2009) but dissimilar to STN responses 417 
following stimulation of the frontal (Magill et al., 2004), sensorimotor (Fujimoto and Kita, 418 
1993) or motor cortex (Kolomiets et al., 2001). The latter - in the majority of cases - are 419 
multi-phasic, with two excitatory phases (equivalent to the present biphasic +/+) often 420 
separated by an inhibition (equivalent to the present triphasic +/-/+). It has been 421 
hypothesized previously (Magill et al., 2004; Kitai and Deniau, 1981) that the short latency 422 
excitation following cortical stimulation appears to be driven by a hyperdirect pathway to 423 
the STN while the later phases of the response arise from polysynaptic interactions, which 424 
are slower to manifest. The inhibition following the first excitation has been hypothesized to 425 
involve the reciprocally connected STN  W globus pallidus (GP) network (Fujimoto and Kitai, 426 
1993). STN excitation may activate GP GABAergic neurons, which in return inhibit the STN. 427 
19 
 
Overall, our data suggests that when the rat is subjected to noxious stimulation, the main 428 
pathway activated to the STN is a fast hyperdirect pathway, originating in part in the PBN. 429 
The fact that we only have a few cells showing an inhibitory second phase (10 biphasic +/- 430 
and 5 triphasic, 15/79) indicates that STN nociceptive cells are rarely closely connected to 431 
the GP and lack GP-STN feed forward control. 432 
 433 
Functionally antagonistic STN neuronal subpopulations have been found in the STN. Specific 434 
GO and STOP cells have been described in PD patients performing a stop signal paradigm, 435 
during motor execution or response inhibition, respectively (Benis et al., 2016). Sub-436 
populations of STN cells have also been shown to exclusively code for reward magnitude (4% 437 
vs 32 % sucrose, Lardeux et al., 2009), error-ƌĞůĂƚĞĚĂĐƚŝǀŝƚǇ ? “KŽƉƐŶĞƵƌŽŶƐ ?, Lardeux et al., 438 
2009), reward value (cocaine or sucrose, Lardeux et al., 2013) and for positive and aversive 439 
reinforcers (Breysse et al, 2015). A major finding of our work is that we were able to 440 
differentiate a subpopulation of STN neurons with a higher spontaneous firing rate on the 441 
basis of the effect of noxious stimuli on general tonic activity. This finding is important since 442 
glutamatergic tone from the STN is likely to have a strong impact on the tonic level of 443 
activity in the basal ganglia network, especially in the output structures (since we 444 
hypothesized that nociceptive-responding STN cells may not be densely connected to GP - 445 
see above). The results from previous computational studies (Gurney et al., 2001) suggest 446 
that tonic control by the STN may adjust the general level of activity of the inhibitory 447 
GABAergic neurons of the BG output structures, known to project to the SC and PBN 448 
(Schneider, 1986; Deniau and Chevalier, 1992). This tonic STN control is hypothesized to be 449 
used by the BG to optimize selection of the most appropriate action. The identification of 450 
separate subpopulations of cells in the STN according to their spontaneous firing rate and 451 
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orientation of the change of their firing rate following the occurrence of noxious stimulation 452 
suggests that the tonic excitatory effects of the STN may not be uniform, although further 453 
work is required to elucidate the connectivity of the STN subpopulations. This mechanism is 454 
important in the context of PD in which STN activity is pathologically increased (Bergman et 455 
al., 1994; Albin et al., 1995), probably disrupting this control. This possibility is further 456 
supported by our results showing enhanced phasic nociceptive responses in a PD rat model, 457 
with an increase in the latency to make nocifensive responses in the hotplate test following 458 
lesions of the STN. As well as interfering with action selection, disrupted STN control in PD 459 
would probably have an impact on the SC and PBN and their role in sensory signal 460 
processing.  461 
 462 
In addition to demonstrating that STN neurons process nociceptive information, we also 463 
assessed whether two subcortical sensori-motor structures from the brain stem transmit 464 
nociceptive signals to the STN. Despite SC nociceptive responses having shorter latencies 465 
than those of STN neurons to the same stimulus, chemical suppression and lesions of SC had 466 
relatively minor effects on the responses of STN to noxious footshock. Lesions of the SC with 467 
acid ibotenic reduced the number of cells that do not respond to noxious stimulation, 468 
suggesting that the SC gates the pool of responding cells in the STN. Our previous work has 469 
demonstrated that the SC is a critical relay for short-latency visual input to DA neurons 470 
(Dommett et al., 2005) but not for short-latency nociceptive input (Coizet et al., 2006), 471 
transmitted by the PBN (Coizet et al., 2010). The current results suggest the same 472 
organization when considering visual and nociceptive input to the STN. The SC is a crucial 473 
structure to transmit visual information while the PBN strongly contributes to the relay of 474 
nociceptive signals. PBN lesions significantly reduced the number of STN cells responding to 475 
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noxious stimuli, sparing a group of cells with short latency short duration responses (figure 476 
7C), possibly activated by nociceptive information relayed by the thalamus (Dostrovsky, 477 
2000a). This nociceptive network linked to the STN is the likely substrate underlying the 478 
successful analgesic effects of STN deep brain stimulation. Kim et al (2012) hypothesized that 479 
STN DBS improves secondary pain symptoms in PD because this stimulation decreases the 480 
abnormally increased muscle tone in patients and may alleviate the primary nociception 481 
processing in the central nervous system. DBS effects are complex and despite the success of 482 
DBS in treating a variety of psychiatric and neurological disorders, the mechanisms 483 
underpinning its therapeutic efficacy remain unclear (McIntyre et al., 2004; Ashkan et al., 484 
2017). DBS is hypothesized to induce Ă  ‘ĨƵŶĐƚŝŽŶĂů ůĞƐŝŽŶ ? ŽĨ ƚŚĞ ^dE  ?&ŽůůĞƚƚ ?  ? ? ? ? ? ? ǀŝĂ485 
depolarization blockade and synaptic inhibition (Beurrier et al., 2001; Dostrovski et al., 486 
2000b), that would lead to a suppression the activity of STN neurons. We hypothesize that 487 
these mechanisms would reduce the pathologically increased firing rate in the STN in PD 488 
(and thus the pain symptoms), as well as nociceptive responses.  489 
 490 
Our current work using anterograde tract tracing neuroanatomy coupled with 3D 491 
reconstruction indicates that a small ascending bundle leaves PBN and then splits into three 492 
massive projections traveling toward the SC, the thalamus and the SNc/STN. Some fibers 493 
from this last ascending pathway continue rostrally to terminate in the amygdala and the 494 
cortex. Comparison of the size of the bundle leaving the PBN and the size of the bundles 495 
traveling to their targets indicate that the number of labelled fibers clearly increase, 496 
suggesting that PBN axons have collaterals. This PBN-STN projection is possibly 497 
interconnected with other PBN efferents, such as the PBN  W amygdala projection, which 498 
partly travels through the STN and has similar types of cells of origin as the PBN cells 499 
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projecting to STN (Sarhan et al., 2005). With DBS effect on axons and fibers (Chiken and 500 
Nambu, 2014), the characterization of this projection and network are important in the 501 
context of STN DBS on pain symptoms. Overall, STN DBS would impact STN and PBN 502 
nociceptive processing but would also modulate PBN-amygdala fibers and possibly other 503 
PBN efferents via the collaterals. The effect of STN DBS would therefore impact many 504 
aspects of pain such as, for example, pain-related emotional reactions when activating the 505 
PBN-amygdaloid connection or neuroendocrine homeostatic regulation in response to pain 506 
with the PBN-hypothalamic pathway (Gauriau and Bernard, 2002). Further experiments are 507 
now needed to fully characterize the effect of STN-DBS on nociceptive processing in our rat 508 
models and how aspects of that network are modulated to achieve a DBS-related analgesic 509 
effect. Pain is a multifaceted experience that can be understood in terms of somatosensory, 510 
affective and cognitive dimension. DBS therapies focused on a single facet of pain, originally 511 
targeting either somatosensory networks or more recently targeting affective regions 512 
(Shirvalkar et al., 2018). The STN is a small structure with functional territories such as 513 
limbic, cognitive and sensory, in close proximity to each other. This would allow the 514 
potential modulation of different modalities of pain and in the future the best DBS electrode 515 
placements within those territories would have to be tested to maximize the analgesic 516 
effect. Finally, numerous non motor symptoms can worsen or improve depending on the 517 
electrical stimulation parameters, as well as the location of the electrode (i.e. Kim et al., 518 
2015). The best parameters of stimulation for nociception would need to take into account 519 
the effect of those parameters on other symptoms of PD. 520 
 521 
Finally, non-neuropathic pain, recently recognized as a frequent and disabling symptom in 522 
PD, is a complaint from many patients suffering from numerous neurodegenerative disease 523 
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ƐƵĐŚ ĂƐ ůǌŚĞŝŵĞƌ ?Ɛ ĚŝƐĞĂƐĞ ĂŶĚ ŽƚŚĞƌ ĚĞŵĞŶƚŝĂƐ ? ŵŽƚŽƌ ŶĞƵƌŽŶ ĚŝƐĞĂƐĞ ? ,ƵŶƚŝŶŐƚŽŶ ?Ɛ524 
disease, spinocerebellar ataxia and spinal muscular atrophy (de Tommaso et al., 2016). Our 525 
findings on the involvement of the STN in nociceptive processing and its link to a nociceptive 526 
network open a new direction for research to explore a possible role of this structure in 527 
other pain syndromes, especially extra-ƉǇƌĂŵŝĚĂů ŽŶĞƐ ůŝŬĞ ,ƵŶƚŝŶŐƚŽŶ ?Ɛ ĚŝƐĞĂƐĞ ?528 
characterized by a dysfunction of the BG. It also opens up the possibility of developing 529 
therapeutic strategies using DBS. A variety of brain sites have been identified for chronic 530 
stimulation procedures to attenuate pain (Davis et al., 1998). These targets include the 531 
thalamus, the periventricular gray nucleus, the cingulate cortex and the motor cortex 532 
(Gorecki et al., 1989, Davis et al., 2000). With the involvement of the STN in a nociceptive 533 
network as demonstrated in our work, the STN-DBS technique can thus be considered in the 534 
future as a new target for the treatment of pain in pharmaco-resistant patients suffering 535 
from previously described neurodegenerative disease, but also, for example, in chronic pain 536 
disease or pharmaco-resistant patients with certain form of migraine which have been 537 
shown to activate the STN (Schwedt et al., 2014).  538 
 539 
METHODS 540 
Electrophysiology - Animals: Fifty male Hooded Lister rats (265-450g) were anaesthetised 541 
with an intra-peritoneal injection of urethane (ethyl carbonate; 1.25g/kg as a 25% aqueous 542 
solution) and mounted in a stereotaxic frame with the skull level. Body temperature was 543 
maintained at 37°C with a thermostatically controlled heating blanket. Two stainless steel 544 
electrodes (E363-1, Plastics One, Roanoke, VA) were inserted into the left hindpaw, one 545 
under the skin of the plantar surface of the foot and the other under the skin of the medial 546 
aspect of the lower leg/ankle. Craniotomies were then performed to allow access to the STN 547 
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and SC or PBN. In accordance with the policy of Lyon1 University, the Grenoble Institut des 548 
Neurosciences (GIN) and the French legislation, experiments were done in compliance with 549 
the European Community Council Directive of November 24, 1986 (86/609/EEC). The 550 
research was authorized by the Direction Départementale des Services Vétérinaires de 551 
ů ?/ƐğƌĞ  WDŝŶŝƐƚğƌĞ ĚĞ ů ?ŐƌŝĐƵůƚƵƌĞ Ğƚ ĚĞ ůĂ WġĐŚĞ ? &ƌĂŶĐĞ  ?ŽŝǌĞƚ sĠƌŽŶŝƋƵe, PhD, permit 552 
number 381003). Every effort was made to minimize the number of animals used and their 553 
suffering during the experimental procedure. All procedures were reviewed and validated by 554 
the "Comité éthique du GIN n°004" agreed by the research ministry (permits number 309 555 
and 310). 556 
 557 
Electrophysiology - STN recordings: Extracellular single unit recordings were made from STN 558 
neurons located contralaterally to the stimulated hindpaw, using glass microelectrodes 559 
pulled via a vertical electrode puller (Narashige Laboratory Instruments Ltd. Tokyo, Japan) 560 
and broken back to a tip diameter of approximately 1 µm (impedances 5- ? ?DA? ?ŵĞĂƐƵƌĞĚ561 
at 135 Hz in 0.9% NaCl). Electrodes were filled with 0.5 M saline and 2% Pontamine Sky Blue 562 
(BDH Chemicals Ltd., Poole, UK). The electrode was lowered into the STN (3.6-4.16 mm 563 
caudal to bregma, 2.0-3.0 mm lateral to midline, 6.8-8.20 mm ventral to the brain surface 564 
according to the atlas Paxinos and Watson (2005) with a hydraulic microdrive (Trent Wells 565 
Inc.). The STN electrode was lowered until a putative STN neuron was identified on the basis 566 
of several criteria: 1) the pattern of activity while lowering the electrode, which was as 567 
follows: an initial absence of activity corresponding to the medial lemniscus fibre track was 568 
followed shortly after by large amplitude, fast bursty neurons located in zona incerta and 569 
then a second absence of action potentials. The return of activity corresponded to the STN; 570 
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2) STN firing rate between 8.5 to 14.7 Hz (Hassani et al., 1996; Kreiss et al., 1996) and 3) STN 571 
firing pattern described as irregular or bursting (Hamani et al., 2004). 572 
 573 
SC/PBN recording and muscimol experiments: Extracellular multiunit recordings were made 574 
simultaneously from the SC or PBN ipsilateral to the STN recording electrode using a 575 
tungsten electrode coupled to a 30-gauge stainless steel injector filled with muscimol (0.25 576 
ʅŐ ?ʅůŝŶƐĂůŝŶĞ ?^ŝŐŵĂ-Aldrich). An angled approach was used in the PBN, with the electrode 577 
tilted caudally by 35°, entering the brain at 11.4 mm caudal to bregma and 1.9-2.0 mm 578 
lateral to midline. PBN was encountered 5.2-5.8 mm below the brain surface. In a second 579 
group of rats, the electrode/injector assembly was introduced vertically into the SC (AP: 6.2-580 
6.5 mm, bregma; ML: 2.1-2.2 mm, bregma; DV: 4.2-4.5 mm, brain surface). The 581 
electrode/injector assembly was lowered into the SC into the lateral part of the deep layers 582 
of the SC, known to project to the STN (Coizet et al., 2009). 583 
 584 
Microinjections were made (0.5 µl at a rate of 0.5 µl/min) via a 10 µl Hamilton syringe 585 
mounted on an infusion pump, connected to the injector by a length of plastic tubing. 586 
Extracellular voltage excursions were amplified, band-pass filtered (300 Hz-10 kHz), digitized 587 
at 10 kHz and recorded directly onto computer disc using a Micro 1401 data acquisition 588 
system (Cambridge Electronic Design [CED] Systems, Cambridge, UK) running CED data 589 
capture software (Spike 2). 590 
 591 
Electrophysiology - Stimulation procedure: As previously described (Coizet et al., 2006; 592 
2010), PBN and SC neurons were identified by their response to noxious footshocks induced 593 
by single pulses (0.5 Hz, 2 ms duration) at an intensity of 5.0 mA. The activity of the cells 594 
26 
 
(single unit in STN and multiunit activity in the PBN or SC) was recorded during a control 595 
period (120 trials of sham stimulation) and during the application of noxious footshocks (120 596 
trials). For the muscimol experiments, an injection of muscimol was made into the PBN or 597 
SC. Typically, a change in local SC/PBN multiunit activity was seen within 60-120 s of the 598 
injection. Noxious electrical footshock stimulation was applied throughout this period, until 599 
either the effects of the drug wore off in the SC/PBN, or the STN cell was lost. After a 600 
complete trial, further STN neurons were tested in the same way. Between 1 and 5 STN cells 601 
were tested in a single subject. 602 
 603 
Nociceptive nature of the stimulation 604 
The electrical stimulation parameters from 3 to 5 mA have previously been shown to be 605 
approximately three times the threshold for activating C-fiber (Chang and Shyu, 2001; 606 
Matthews and Dickenson, 2001; Carpenter et al., 2003), to produce reliabůĞɷĂŶĚ-fiber 607 
responses in the anesthetized rat spinal cord (Urch et al., 2003) and c-fos expression in the 608 
nociceptive superficial lamina of the spinal cord (Coizet et al., 2006). They also activate the 609 
SC (Coizet et al., 2006), the PBN (Coizet et al., 2010) and the dopaminergic neurons (Coizet et 610 
al., 2006, 2010) in a qualitatively similar way than a mechanical noxious pinch with a teethed 611 
forceps. 612 
To ascertain the noxious nature of our stimulation, we performed three control tests based 613 
on the previous observations. i) We first performed an intensity test on a group of STN cells 614 
following footshocks with intensities ranging from 0 to 5 mA. Among the 17 STN neurons 615 
responding to the maximum 5 mA stimulation, a decrease of intensity was followed by a 616 
decrease of the number of responding cells following a 4 mA (n = 12) and a 3 mA (n = 7) 617 
stimulation. None of those cells showed a response for intensities under the threshold of 3 618 
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mA (figure 10A, supplementary results). Furthermore, analysis performed on the 7 cells 619 
responding to 3, 4 and 5 mA showed a significant effect of the intensity of the stimulation 620 
when considering the maximum amplitude (ANOVA  W repeated measure: F [2,20] = 11.51, p 621 
< 0.01) and the magnitude (ANOVA  W repeated measure : F[2,20] = 17.55, p < 0.001): in both 622 
cases there was a significant increase in the response parameters with the increase in the 623 
intensity (Tukey-Kramer post-hoc comparison  W maximum amplitude: 3 mA vs 5 mA, p < 624 
0.01, 4mA vs 5 mA, p < 0.05; magnitude: 3 mA vs 4 mA, p < 0.05; 3 mA vs 5 mA, p < 0.001). ii) 625 
We compared the effect of a mechanical pinch with a teethed forceps and a 5 mA footshock 626 
on STN neuron responses. All the cells responding to the manual pinch showed a 627 
qualitatively similar excitation to the footshock (figure 10B, supplementary results), while 628 
none of the cells unresponsive to pinch were activated by footshock. iii) As previously 629 
reported (Coizet et al., 2006, 2010), noxious footshock of 5mA for an hour induced the 630 
expression of c-fos labeling within the medial part of the ipsilateral superficial layers of the 631 
lumbar cord, especially layers I and II, although layers III-V also contained some labeling. In 632 
control animals, where electrodes were implanted but the stimulation was not delivered, 633 
substantially lower levels of c-fos were observed (figure below D). These results confirm that 634 
the footshock used in the present study was activating nociceptive elements in the lumbar 635 
spinal cord (Besson, 1987; Almeida et al., 2004) consistent with known somatotopic 636 
representations of the hindfoot; i.e. primary afferents from the foot terminate medially 637 
(Sweet and Woolf, 1985). 638 
 639 
Electrophysiology - Histology and analysis: The position of SC and PBN recording sites were 640 
marked with a small lesion caused by passing 10 PA DC current for 2.5 min through the 641 
tungsten recording electrode. The final recording site for the STN recording electrode was 642 
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marked by passing a constant cathodal current of 27.5 µA (constant current source) through 643 
the electrode for a period of 30 min to eject Pontamine Sky Blue. Animals were then killed 644 
by an overdose of pentobarbital and perfused with 0.9 % saline followed by 4 % 645 
paraformaldehyde. Brains were removed and postfixed overnight in 4% paraformaldehyde 646 
at 4 °C, before being transferred into sucrose for 36 h. Serial coronal (30 µm) sections were 647 
cut, mounted on slides and processed with a Nissl stain (Cresyl Violet). Once sections had 648 
been processed, recording sites were reconstructed onto sections taken from the atlas of 649 
Paxinos and Watson (2005). 650 
 651 
Peri-stimulus time interval histograms (PSTHs) were constructed based on SC/PBN multi-unit 652 
(bin width 1 ms) and STN single-unit data (bin width 10 ms). PSTHs were imported into an 653 
Excel program (Peter Furness, University of Sheffield, Coizet et al., 2006, 2009, 2010; 654 
Dommett et al., 2005) which determined the following response characteristics: i) Baseline 655 
activity: was the mean number of single- multi-unit events during the 500 ms bins prior to 656 
the footshock. ii) Response latency: The latency of a visually-evoked response was marked as 657 
the point when the value of post-stimulation events exceeded 1.96 S.D. of the baseline 658 
mean. (iii) Response duration: Response offset was recorded when post-stimulation activity 659 
returned to a value 1.96 S.D. of the baseline mean. iii) Amplitude of the response is the 660 
maximum amplitude during the response. iv) Magnitude of the response: is the mean 661 
number of single- multi-unit events between response onset and offset minus the baseline 662 
mean.  663 
 664 
Lesion procedure in SC and PBN 665 
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Fourteen rats received a unilateral ibotenic acid lesion of the SC or the PBN. Each rat was 666 
anesthetized with isofluorane (5 % for the induction and 1-2 % for maintenance) and placed 667 
in a stereotaxic instrument. A 30-gauge metal injector needle filled with ibotenic acid (20 668 
µg/µl in phosphate buffered saline) was introduced using the same coordinates as for the 669 
electrophysiological procedure. The injections in the PBN were made according to a 670 
previously published procedure by Reilly and Trifunovic (2000; 2001) with 671 
electrophysiological guidance to improve the accuracy of the location of the lesion. The 672 
microinjections were made (0.5 µl/min) in the SC (0.5-0.65 µl) and the PBN (0.3-0.5 µl) as for 673 
the muscimol injections (see above). The cannula remained in situ for a further 10 min to 674 
minimize the spread of neurotoxin back along the track before the cannula was removed 675 
and the incision was closed. 676 
 677 
Lesion procedure in STN and hot plate test 678 
Twenty Long Evans rats were anesthetized with ketamine (100 mg/Kg, s.c., Imalgène 1000, 679 
Merial, Lyon, France) and medetomidine (0,85 mg/Kg, s.c., Domitor, Orion Pharma, Espoo, 680 
Finland). Rats were secured in Kopf stereotaxic apparatus. Then, a unilateral 30-gauge 681 
stainless-steel injector needle connected by Tygon tubing (Saint Gobain performance 682 
pastics) with a 10µL Hamilton microsyringe (Bonaduz, Switzerland) fixed on a micropump 683 
(CMA, Kista, Sweden) was positioned into the STN. Coordinates for the aimed site were (with 684 
tooth bar set at -3.3mm): anteposterior -3.72mm; lateral ±2.4mm from bregma; 685 
dorsoventral -8.4mm from skull (Paxinos & Watson, 2005). Rats received either a bilateral 686 
injection of ibotenic acid (9.4µg/µL, AbCam Biochemical, Cambridge, UK; STN-lesioned 687 
group, n=12) or vehicle solution (phosphate buffer, 0.1M; Sham control group, n=8). The 688 
volume injected was 0.5µL per side infused over 3 min. The injectors were left in place for 3 689 
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min to allow diffusion. At the end of surgery, medetomidine was reversed by 0.2 mg (4.28 690 
mg/Kg, s.c.) atipamezole (Antisedan, Orion Pharma, Espoo, Finland). Three weeks after the 691 
surgery, all the animals performed the hot plate test. Each rat was placed on a heated metal 692 
plate (53°) surrounded by a transparent cylinder. The experimenter was constantly watching 693 
the rat ?ƐďĞŚĂǀŝŽƵƌĚƵƌŝŶŐƚŚĞƚĞƐƚƚŽŵĞĂƐƵƌĞƚŚĞůĂƚĞŶĐǇof the first sign of paw licking or 694 
jumping and to quickly remove the animals from the apparatus. The maximum time on the 695 
ŚŽƚ ƉůĂĐĞ ǁĂƐ ƐĞƚ ƚŽ  ? ? Ɛ ? dŚĞ ƌĂƚ ?Ɛ ďĞŚĂǀŝŽƵƌ ǁĂƐ ĂůƐŽvideo recorded online on the 696 
computer for a second finer analysis.  697 
 698 
6-OHDA lesions 699 
Rats were anesthetised with an intraperitoneal injection of a mixture of ketamine-xylazine 700 
(0.765/1.1 ml; 1 ml/kg, i.p.) and placed in a stereotaxic frame with the skull level. All the 701 
microinjections were made via a sharpened 30G injection cannula connected with 702 
polyethylene tubing to a 10-µl Hamilton syringe driven by an infusion pump (0.5 µl/min). 703 
After the injection, the cannula was left in place for a further 5 min to allow diffusion. 704 
Animals were divided into two groups: i) A group with a total dopaminergic lesion (n = 9), in 705 
which 3 µl of 6-OHDA (Sigma-Aldrich, 3 mg/ml in sterile 0.9% NaCl and 0.1% ascorbic acid) 706 
was injected into the left SNc using the following stereotaxic coordinates: AP: + 3.0 mm; ML : 707 
+ 2.1 mm and DV: + 2.4 mm from interaural zero mm; ii) A control group with no injection of 708 
the toxin (n = 9).  709 
The extent of the DA denervation following the 6-OHDA injections in the SNc was 710 
determined using tyrosine hydroxylase (TH) immunohistochemistry. To reveal TH, the 711 
sections were washed and incubated in a blocking solution containing 0.1M PB with 0.3% of 712 
triton X-100 (TX), 2.5% of Bovine Serum Albumin (BSA) and 5% normal horse serum (NHS) for 713 
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2 h before being transferred overnight in a 0.1M PB-TX 0.3% with 1% BSA and 2% NHS 714 
containing the primary mouse monoclonal TH antibody, diluted 1:3000 (Chemicon, 715 
Hampshire, UK). The following day, sections were washed in 0.1M PB and incubated with the 716 
secondary antibody, biotinylated antimouse made in horse (in a dilution of 1:1000 in 0.1M 717 
PB-TX 0.3% with 2% NHS) for 2 h. Following further washes in 0.1M PB, the sections were 718 
exposed to the elite Vectastain ABC reagent (Vector Laboratories, Burlingame, CA, USA) 719 
diluted 1:100 in PB-TX 0.3%, for 2 h. Again following washes in 0.1M PB, immunoreactivity 720 
was revealed by exposure to VIP (Vector Laboratories) for 2 min which produced a purple 721 
reaction product. Sections were then mounted onto gelled slides, dehydrated through 722 
alcohols and cleared in xylene before being coverslipped with DPX. TH-immunolabelling of 723 
DA neurons and terminals was evaluated using a light microscope (Nikon, Eclipse 80i, 724 
TRIBVN, Chatillon, France) coupled to the ICS Framework computerized image analysis 725 
system (TRIBVN, 2.9.2 version, Chatillon, France). For quantification, TH-labeled coronal 726 
sections of SNc (AP -5.3 mm to -5.8 mm from Bregma) and striatum (AP 0.20 mm to -0.30 727 
mm from bregma) were digitized using a Pike F-421C camera (ALLIED Vision Technologies 728 
Stradtroda, Germany). Optical densities (OD) were measured for the denervated and non-729 
denervated territories of the lesioned animals for each section and were compared to those 730 
in the homologous regions of the sham-operated animals. 731 
 732 
Statistics 733 
The statistical reliability of differences between response latencies for the SC/PBN and STN, 734 
and comparisons of response duration, amplitude and magnitude before and after SC/PBN 735 
injections of muscimol was made using parametric (ANOVA, t-test) or non-parametric 736 
(Wilcoxon, Mann-Whitney) statistical tests according to the normality of the data. STN 737 
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baseline firing rate change before and after the noxious stimulation was assessed during the 738 
500 ms before the sham and noxious stimulation. The data were imported in MATLAB, bined 739 
and compared using a Wilcoxon test. STN firing pattern was also assessed using MATLAB 740 
according to the methodology developed by Piallat et al. (2001). Neurons were classified as 741 
irregular, regular or bursting according to the interspike distributions and autocorrelograms. 742 
Burst activity showed a wide or bimodal interval interspike distribution and a significant 743 
single peak on the autocorrelation function. Irregular activity was characterised by a wide 744 
interval interspike distribution and a flat autocorrelogram. Regular activity was characterised 745 
by a narrow interval interspike distribution and an autocorrelogram with multiple regular 746 
peaks. 747 
 748 
Anatomy -animals: We used 14 male Long Evans rats (350-460 g, Janvier, France). Animals 749 
were anaesthetised with an intraperitoneal injection of a mixture of Ketaset (0.765 ml/kg) 750 
and Rompun (1.1 ml/kg).  751 
 752 
Anatomy - anterograde experiment: Single injections of the anterograde tracers 753 
biotinylated dextran amine (BDA: Sigma-Aldrich) or Phaseolus vulgaris leucoagglutinin (PHA-754 
L: Vector Laboratories, Peterborough, UK) were made into the PBN. An angled approach was 755 
used as previously described (Coizet et al., 2010). BDA (10 % in phosphate buffer; PB) was 756 
pressure ejected in volumes of 30-90 nl via a glass micropipette (20 µm diameter tip) using a 757 
compressed air injection system, while PHA-L was ejected iontophoretically (5µA anodal 758 
current applied to a 2.5 % solution in PB, 7 s on/off for 15-20 min).  759 
 760 
33 
 
Anatomy - retrograde experiment: Small (10-20 nl) pressure injections of the retrograde 761 
tracers Cholera toxin subunit B (CTB, 1 % solution in phosphate buffer) or the fluorescent 762 
tracer Fluorogold (FG, 4 % in distilled water) were made into the STN. After allowing 7 days 763 
for the transport of tracers, animals were re-anesthetised with pentobarbitane and perfused 764 
transcardially. The brains were placed immediately in 4 % PFA overnight before being 765 
cryoprotected by immersion in sucrose solution (20% in 0.1 M PB) for at least 36 hours. 766 
Three series of coronal or sagittal sections (30 µm) were cut on a freezing microtome and 767 
collected in 0.1 M PB for further immunohistochemistry processing, except for tissue 768 
containing FG where one series was collected directly onto slides, allowed to dry in a light 769 
protected box and coverslipped with DPX mountant. 770 
 771 
Anatomy  ? histology: To reveal the tracers, (BDA, PHA-L, CTB), free-floating sections were 772 
washed with 0.1 M PB followed by 0.1 M PB containing 0.3 % Triton X-100 (PB-TX) for 30 773 
min. For animals injected with PHA-L or CTB, the sections were incubated overnight in 774 
primary antibody solution (goat anti-PHA-L, 1:1,000 dilution, Vector, or goat anti-CTB, 775 
1:4,000 dilution, Quadratech). The next day, sections were washed with PB-TX and 776 
incubated for 2 h in biotinylated rabbit anti-goat IgG (1:100, Vector, in PB-TX containing 2 % 777 
normal rabbit serum). After 30 min washing, all the sections were incubated in Elite 778 
Vectastain ABC reagent (Vector, 1:100 in PB-TX) for 2 h. The peroxidase associated with the 779 
tracers was revealed by reacting tissue with H2O2 for approximately 1 min using nickel-780 
enhanced diaminobenzidine (DAB) as the chromogen for BDA and CTB (black reaction 781 
product) and using nickel-free DAB for PHA-L (brown reaction product). Finally, sections 782 
were washed in PB, mounted on gelatine-coated slides, dehydrated in graded dilutions of 783 
alcohol, cleared in xylene and coverslipped in DPX.  784 
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 785 
Anatomy  ? analysis: Following injections of anterograde tracers into the PBN, three coronal 786 
sections through the STN separated by ~ 0.5 mm (equivalent to -3.6, -3.8 and -4.1 mm caudal 787 
to bregma in the atlas of Paxinos and Watson, 2005) or three sagittal sections (equivalent to 788 
1.9, 2.4 and 2.9 lateral to bregma) were selected for analysis. Sections of interest were 789 
digitized using a light microscope (Nikon, Eclipse 80i, TRIBVN, 2.9.2 version, Chatillon, 790 
France) coupled to the ICS Framework computerized image analysis system (TRIBVN, 2.9.2 791 
version, Chatillon, France) and a Pike F-421C camera (ALLIED Vision Technologies Stradtroda, 792 
Germany).  793 
The location of retrogradely labelled cells was plotted on four coronal sections through the 794 
PBN separated by ~ 0.5 mm (equivalent to -8.8, -9.3, -9.8 caudal to bregma). A series of 795 
digital images (magnification 10 X) were taken and imported into a graphics program 796 
(Macromedia Freehand) where they were montaged. The borders and layers of the PBN 797 
were drawn over the montage. The location of anterogradely labelled axons and terminals 798 
was plotted on sagittal sections from 1.9 to 2.9 lateral from bregma. Fibres and terminals 799 
associated with the injections were traced with the aid of a pen tablet (intuos) with a 800 
microscope equipped with a camera lucida and a graphics program (Microsoft PowerPoint). 801 
By focusing on different depths in the brain sections, it was possible to produce a drawing 802 
that contained all labelled elements in the section. 803 
 804 
For the 3D reconstruction, the most representative example was selected and series of 805 
sagittal sections containing PBN and STN were digitized using a light microscope (Nikon, 806 
Eclipse 80i, TRIBVN, 2.9.2 version, Chatillon, France) coupled to the ICS Framework 807 
computerized image analysis system (TRIBVN, 2.9.2 version, Chatillon, France) and a Pike F-808 
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421C camera (ALLIED Vision Technologies Stradtroda, Germany). Digitized images were 809 
converted into a .tiff format and individually exported in Adobe Photoshop to create 810 
individual .tiff files with the same dimension. A stack of 2D sagittal sections was then created 811 
using Cygwin (Cygwin TM sources) and IMOD package software (Boulder laboratory for 3D 812 
Electron Microscopy of Cells, University of Colorado, Boulder, CO) (Kremer et al., 1996). As 813 
previously described (Coizet et al., 2017; Mailly et al., 2010), sections were aligned with the 814 
Midas program from IMOD using manual rigid body transformations. The stack was opened 815 
in IMOD, where the structures of interest were delineated including the PBN, SNr / SNc, STN, 816 
and SC. The injection site and individual ascending labelled axons were drawn in IMOD 817 
directly on the digitized images. This process also created a 3D reconstruction of ascending 818 
fibers. 819 
 820 
Acknowledgement: The Photonic Imaging Center of Grenoble Institute Neuroscience (Univ 821 
Grenoble Alpes  W Inserm U1216) is part of the ISdV core facility and certified by the IBiSA 822 
label. Région Rhône-Alpes  823 
 824 
Conflicts of interest: The authors have declared that no conflict of interest exists. 825 
 826 
REFERENCES 827 
The functional anatomy of disorders of the basal ganglia 828 
RL Albin, AB Young and JB Penney (1995) 829 
 Trends in Neuroscience 18(2): 63-64. 830 
 831 
Parallel organization of functionally segregated circuits linking basal ganglia and cortex 832 
GE Alexander, MR DeLong and PL Strick (1986) 833 
Annual Review of Neuroscience 9: 357-381. 834 
 835 
36 
 
Afferent pain pathways: a neuroanatomical review  836 
TF Almeida, S Roizenblatt and S Tufik (2004)  837 
Brain Research 1000: 40-56. 838 
DOI: 10.1016/j.brainres.2003.10.073 839 
 840 
Insights into the mechanisms of deep brain stimulation 841 
K Ashkan, P Rogers, H Bergman and I Ughratdar (2017) 842 
Nature Reviews. Neurology 13: 548-554. 843 
DOI: 10.1038/nrneurol.2017.105 844 
 845 
Six questions on the subthalamic nucleus: lessons from animal models and from 846 
stimulated patients. Neuroscience 847 
C Baunez, J Yelnik and L Mallet (2011) 848 
Neuroscience 198: 193-204. 849 
DOI: 10.1016/j.neuroscience.2011.09.059. 850 
 851 
The Effects of Mechanical and Thermal Stimuli on Local Field Potentials and Single Unit 852 
ĐƚŝǀŝƚǇŝŶWĂƌŬŝŶƐŽŶ ?ƐŝƐĞĂƐĞWĂƚŝĞŶƚƐ 853 
A Belasen, Y Youn, L Gee, J Prusik, B Lai, A Ramirez-Zamora, K Rizvi, P Yeung, DS Shin, C 854 
Argoff and JG Pilitis (2016) 855 
Neuromodulation 19(7): 698-707.  856 
DOI: 10.1111/ner.12453. 857 
 858 
Response inhibition rapidly increases single-neuron responses in the subthalamic nucleus 859 
of patients with Parkinson's disease 860 
D Benis, O David, B Piallat, A Kibleur, L Goetz, M Bhattacharjee, V Fraix, E Seigneuret, P 861 
Krack, S Chabardès and J Bastin (2016) 862 
Cortex 84: 111-123.  863 
DOI: 10.1016/j.cortex.2016.09.006. 864 
 865 
Pathophysiology of pain and fatigue in Parkinson's disease 866 
A Berardelli, A Conte, G Fabbrini, M Bologna, A Latorre, L Rocchi and A Suppa (2012) 867 
37 
 
Parkinsonism & Related Disorders 18 Suppl 1: S226-8.  868 
DOI: 10.1016/S1353-8020(11)70069-4. 869 
 870 
The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism 871 
H Bergman, B Wichmann, B Karmon and R DeLong (1994)  872 
Journal of Neurophysiologie 72: 507 W520.  873 
DOI: 10.1152/jn.1994.72.2.507. 874 
 875 
A possible spino (trigemino)-ponto-amygdaloid pathway for pain 876 
JF Bernard, M Peschanski and JM Besson (1989) 877 
Neuroscience Letters 100(1-3): 83-88. 878 
 879 
Peripheral and spinal mechanisms of nociception 880 
JM Besson (1987) 881 
Physiological Reviews 67:67-187. 882 
 883 
High-frequency stimulation produces a transient blockade of voltage-gated currents in 884 
subthalamic neurons 885 
C Beurrier, B Bioulac, J Audin and C Hammond (2001) 886 
Journal of Neurophysiology 85: 1351-6. 887 
DOI: 10.1152/jn.2001.85.4.1351 888 
 889 
Nociceptive brain activation in patients with neuropathic pain related to Parkinson's 890 
disease 891 
C Brefel-Courbon, F Ory-Magne, C Thalamas, P Payoux and Rascol O (2013) 892 
Parkinsonism & Related Disorders 19(5): 548-52.  893 
DOI: 10.1016/j.parkreldis.2013.02.003. 894 
 895 
The good and bad differentially encoded within the subthalamic nucleus in rats 896 
E Breysse, Y Pelloux, C Baunez (2015) 897 
eNeuro 15: 2(5).  898 
DOI: 10.1523/ENEURO.0014-15.2015. 899 
38 
 
 900 
Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde 901 
horseradish peroxidase study in the rat 902 
NS Canteras, SJ Shammah-Lagnado, BA Silva and JA Ricardo (1990)  903 
Brain Research 513(1): 43-59. 904 
 905 
Disrupting neuronal transmission: mechanism of DBS? 906 
S Chiken and A Nambu (2014)  907 
Frontiers in Systems Neuroscience 8: 33.  908 
DOI: 10.1111/ejn.12711. 909 
 910 
The role of the basal ganglia in nociception and pain 911 
EH Chudler and WK Dong (1995) 912 
Pain 60(1): 3-38. 913 
 914 
Nociceptive responses of dopaminergic neurones modulated by experimental 915 
manipulations of the superior colliculus in rat 916 
V Coizet, E Dommett, PG Overton and P Redgrave (2006) 917 
Neuroscience 139(4): 1479-1493.  918 
DOI: 10.1016/j.neuroscience.2006.01.030 919 
 920 
Short-latency visual input to the subthalamic nucleus is provided by the midbrain superior 921 
colliculus 922 
V Coizet, J Graham, J Moss, P Bolam, M Savasta, J McHaffie, P Redgrave and P Overton 923 
(2009)  924 
Journal of Neuroscience 29(17): 5701-09.  925 
DOI: 10.1523/JNEUROSCI.0247-09.2009. 926 
 927 
The parabrachial nucleus is a critical link in the transmission of short latency nociceptive 928 
information to midbrain dopaminergic neurons 929 
V Coizet, EJ Dommett, EM Klop, P Redgrave and PG Overton (2010) 930 
Neuroscience 168(1): 263-72.  931 
39 
 
DOI: 10.1016/j.neuroscience.2010.03.049. 932 
 933 
The Rat prefronto-striatal and prefronto-thalamic bundles analysed in 3D: Evidence for a 934 
topographical organization 935 
V Coizet, S Heilbronner, C Carcenac, P Mailly, J Lehman, M Savasta, O David, JM Deniau, HJ 936 
Groenewegen and SN Haber (2017) 937 
Journal of Neuroscience 37(10): 2539-2554.  938 
DOI: 10.1523/JNEUROSCI.3304-16.2017. 939 
 940 
Pathophysiology of somatosensory abnormalities in Parkinson disease 941 
A Conte, N Khan, G Defazio, JC Rothwell and A Berardelli (2013) 942 
Nature Reviews. Neurology 9(12): 687-97.  943 
DOI: 10.1038/nrneurol.2013.224. 944 
 945 
Distribution of brainstem projections from spinal lamina I neurons in the cat and the 946 
monkey 947 
AD Craig (1995) 948 
Journal of Comparative Neurology 361: 225 W248. 949 
DOI: 10.1002/cne.903610204 950 
 951 
Effects of deep brain stimulation on pain and other non-motor symptoms in Parkinson 952 
disease 953 
RG Cury, R Galhardoni, ET Fonoff, MG Dos Santos Ghilardi, F Fonoff, D Arnaut, ML 954 
Myczkowski, MA Marcolin, E Bor-Seng-Shu, ER Barbosa, MJ Teixeira and D Ciampi de 955 
Andrade (2014) Neurology 83(16): 1403-9.  956 
DOI: 10.1212/WNL.0000000000000887. 957 
 958 
Brain targets for pain control 959 
KD Davis, AM Lozano, RR Tasker and JO Dostrovsky (1998) 960 
Sterotactic and functional neurosurgery 71: 173-179. 961 
DOI: 10.1159/000029661 962 
 963 
40 
 
Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron 964 
emission tomography study 965 
E Dellapina, A Gerdelat-Mas, F Ory-Magne, L Pourcel, M Galitzky, F Calvas, M Simonetta-966 
Moreau, C Thalamis, P Payoux and C Brefel-Courbon (2011) 967 
Movement Disorders 26(1): 153-157. 968 
DOI: 10.1002/mds.23406 969 
 970 
The lamellar organization of the rat substantia nigra pars reticulata  ? distribution of 971 
projection neurons 972 
JM Deniau and G Chevalier (1992) 973 
Neuroscience 46: 361 W377. 974 
 975 
Quantitative measurement of pain sensation in patients with Parkinson disease 976 
R Djaldetti, A Shifrin, Z Rogowski, E Sprecher, E Melamed and D Yarnitsky (2004) 977 
Neurology 62: 2171-2175. 978 
 979 
How visual stimuli activate dopaminergic neurons at short latency 980 
E Dommett, V Coizet, CD Blaha, J Martindale, V Lefebvre, N Walton, JEW Mayhew, PG 981 
Overton and P Redgrave (2005) 982 
Science 307, 1476-1479.  983 
DOI: 10.1126/science.1107026 984 
 985 
Role of thalamus in pain 986 
JO Dostrovsky (2000a) 987 
Progress in brain research 129: 245-257.  988 
DOI: 10.1016/S0079-6123(00)29018-3. 989 
 990 
Microstimulation-induced inhibition of neuronal firing in human globus pallidus 991 
JO Dostrovsky, R Levy, JP Wu, WD Hutchinson, RR Tasker and AM Lozano (2000b) 992 
Journal of Neurophysiology 84(1): 570-4. 993 
DOI: 10.1152/jn.2000.84.1.570 994 
 995 
41 
 
The surgical treatment of Parkinson's disease 996 
KA Follett (2000)  997 
Annual Review of Medicine 51: 135-147. 998 
DOI: 10.1146/annurev.med.51.1.135 999 
 1000 
Response characteristics of subthalamic neurons to the stimulation of the sensorimotor 1001 
cortex in the rat 1002 
K Fujimoto and H Kita (1993) 1003 
Brain Research 609(1-2): 185-92. 1004 
 1005 
Pain pathways and parabrachial circuits in the rat 1006 
C Gauriau and JF Bernard (2002) 1007 
Experimental Physiology 87: 251-258. 1008 
 1009 
Thalamic stimulation and recording in patients with deafferentation and central pain 1010 
J Gorecki, T Hirayama, JO Dostrovsky, RR Tasker and FA Lenz (1989) 1011 
Stereotactic and Functional Neurosurgery 52(2-4):219-26.  1012 
DOI: 10.1159/000099504. 1013 
 1014 
A computational model of action selection in the basal ganglia. I. A new functional 1015 
anatomy 1016 
K Gurney, TJ Prescott and P Redgrave (2001) 1017 
Biological Cybernetics 84: 401-410.  1018 
DOI: 10.1007/PL00007984. 1019 
 1020 
Pain in Parkinson's disease 1021 
AD Ha and J Jankovic (2011).  1022 
Movement Disorders 27(4): 485-91.  1023 
DOI: 10.1002/mds.23959. 1024 
 1025 
The subthalamic nucleus in the context of movements disorders 1026 
C Hamani, JA Saint-Cyr, J Fraser, M Kaplitt and AM Lozano (2004) 1027 
42 
 
Brain 127: 4-20.  1028 
DOI: 10.1093/brain/awh029. 1029 
 1030 
Peripheral input to the rat subthalamic nucleus, an electrophysiological study 1031 
C Hammond, JM Deniau, B Rouzaire-Dubois and J Feger (1978) 1032 
Neuroscience Letters 9(2-3): 171-6. 1033 
 1034 
WĂŝŶŝƐĐŽŵŵŽŶŝŶWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ 1035 
Hanagasi HA, Akat S, Gurvit H, Yazici J and Emre M (2010) 1036 
Clinical Neurology and Neurosurgery 113(1): 11-3. 1037 
DOI: 10.1016/j.clineuro.2010.07.024. 1038 
 1039 
Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of 1040 
disinhibition via the globus pallidus 1041 
OK Hassani, M Mouroux and J Feger (1996) 1042 
Neuroscience 72: 105 W115. 1043 
 1044 
Sensory (nociceptive) stimulation evokes Fos expression in the subthalamus of 1045 
hemiparkinsonian rats 1046 
CE Heise, S Reyes and J Mitrofanis (2008) 1047 
 Neurological Research 30(3): 277-84.  1048 
DOI: 10.1179/016164107X235455. 1049 
 1050 
Spinal lamina I projection neurons in the rat: collateral innervation of parabrachial area 1051 
and thalamus 1052 
JL Hylden, F Anton and RL Nahin (1989) 1053 
Neuroscience 28(1): 27-37. 1054 
 1055 
A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition 1056 
M Jahanshahi, I Obeso, JC Rothwell and JA Obeso (2015) 1057 
Nature Review Neuroscience 16(12): 719-32.  1058 
DOI: 10.1038/nrn4038. 1059 
43 
 
 1060 
Chronic subthalamic deep brain stimulation improves pain in Parkinson disease 1061 
HJ Kim, SH Paek, JY Kim, JY Lee, YH Lim, MR Kim, DG Kim and BS Jeon (2008) 1062 
Journal of Neurology 255(12): 1889-94.  1063 
DOI: 10.1007/s00415-009-0908-0. 1064 
 1065 
The benefit of subthalamic deep brain stimulation for pain in Parkinson disease: a 2-year 1066 
follow-up study 1067 
HJ Kim, BS Jeon, JY Lee, SH Paek and DG Kim (2012) 1068 
Neurosurgery 70(1): 18-23. 1069 
DOI: 10.1227/NEU.0b013e3182266664. 1070 
 1071 
Cortical inputs to the subthalamus: intracellular analysis 1072 
ST Kitai and JM Deniau (1981) 1073 
Brain Research 214(2): 411-5. 1074 
 1075 
An update of the impact of deep brain stimulation on non-motor symptoms in Parkinson's 1076 
disease 1077 
L Klingelhoefer, M Samuel, KR Chaudhuri and K Ashkan (2014) 1078 
Journal of Parkinson͛s Disease 4(2): 289-300.  1079 
DOI: 10.3233/JPD-130273. 1080 
 1081 
In cat four times as many lamina I neurons project to the parabrachial nuclei and twice as 1082 
many to the periaqueductal gray as to the thalamus 1083 
EM Klop, LJ Mouton, R Hulsebosch, J Boers and G Holstege (2005) 1084 
Neuroscience 134(1): 189-97.  1085 
DOI: 10.1016/j.neuroscience.2005.03.035. 1086 
 1087 
Segregation and convergence of information flow through the cortico-subthalamic 1088 
pathways 1089 
BP Kolomiets, JM Deniau, P Mailly, A Ménétrey, J Glowinski and AM Thierry (2001) 1090 
Journal of Neuroscience 21: 5764-5772. 1091 
44 
 
 1092 
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced 1093 
Parkinson's disease 1094 
P Krack, A Batir, N Van Blercom, S Chabardes, V Fraix, C Ardouin, A Koudsie, PD Limousin, A 1095 
Benazzouz, JF LeBas, AL Benabid and P Pollak (2003)  1096 
The New England Journal of Medicine 349(20): 1925-34.  1097 
DOI: 10.1056/NEJMoa035275. 1098 
 1099 
Apomorphine and dopamine D1 receptor agonists increase the firing rates of subthalamic 1100 
nucleus neurons 1101 
DS Kreiss, LA Anderson and JR Walters (1996) 1102 
Neuroscience 72(3): 863-76. 1103 
 1104 
Computer visualization of three-dimensional image data using IMOD 1105 
JR Kremer, DN Mastronarde and JR McIntosh (1996) 1106 
Journal of Structural Biology 116: 71-76. 1107 
DOI: 10.1006/jsbi.1996.0013. 1108 
 1109 
Beyond the reward pathway: coding reward magnitude and error in the rat subthalamic 1110 
nucleus 1111 
S Lardeux, R Pernaud, D Paleressompoulle and C Baunez (2009) 1112 
Journal of Neurophysiology 102(4): 2526-2537.  1113 
DOI: 10.1152/jn.91009.2008. 1114 
 1115 
Different populations of subthalamic neurons encode cocaine vs. sucrose reward and 1116 
predict future error 1117 
S Lardeux, D Paleressompoulle, R Pernaud, M Cador and C Baunez (2013) 1118 
 Journal of Neurophysiology 110(7): 1497-1510.  1119 
DOI: 10.1152/jn.00160.2013. 1120 
 1121 
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease 1122 
P Limousin, P Krack, P Pollak, A Benazzouz, C Ardouin, D Hoffmann and AL Benabid (1998)  1123 
45 
 
The New England Journal of Medicine 339(16): 1105-1111.  1124 
DOI: 10.1056/NEJM199810153391603. 1125 
 1126 
Synchronous Unit Activity and Local Field Potentials Evoked in the Subthalamic Nucleus by 1127 
Cortical Stimulation 1128 
PJ Magill, A Sharott, MD Bevan, P Brown and JP Bolam (2004) 1129 
Journal of Neurophysiology 92: 700-714. 1130 
DOI: 10.1152/jn.00134.2004. 1131 
 1132 
A 3D multi-modal and multi-dimensional digital brain model as a framework for data 1133 
sharing 1134 
P Mailly, SN Haber, HJ Groenewegen and JM Deniau (2010) 1135 
Journal of Neuroscience Methods 194, 56-63. 1136 
DOI: 10.1016/j.jneumeth.2009.12.014. 1137 
 1138 
Visual and oculomotor functions of monkey subthalamic nucleus 1139 
M Matsumura, J Kojima, TW Gardiner and O Hikosaka (1992) 1140 
Journal of Neurophysiology 67: 1615-1632. 1141 
DOI: 10.1152/jn.1992.67.6.1615. 1142 
 1143 
Nociceptive neurons in rat superior colliculus: response properties, topography, and 1144 
functional implications 1145 
JG McHaffie, CQ Kao and BE Stein (1989) 1146 
Journal of Neurophysiology 62(2): 510-525.  1147 
DOI: 10.1152/jn.1989.62.2.510. 1148 
 1149 
Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or 1150 
both 1151 
CC McIntyre, M Savasta, L Kerkerian-Le Goff and JL Vitek (2004) 1152 
Clinical Neurophysiology 115(6): 1239-48. 1153 
DOI: 10.1016/j.clinph.2003.12.024 1154 
 1155 
46 
 
The Rat Brain in Stereotaxic Coordinates 1156 
G Paxinos and C Watson (2005) 1157 
Academic Press, Sydney 1158 
 1159 
Subthalamic neuronal firing in obsessive-compulsive disorder and Parkinson disease 1160 
B Piallat, M Polosan, V Fraix, L Goetz, O David, A Fenoy, N Torres, JL Quesada, E Seigneuret, P 1161 
Pollak, P Krack, T Bougerol, AL Benabid and S Chabardès (2011) 1162 
Annals of Neurology 69: 793-802.  1163 
DOI: 10.1002/ana.22222. 1164 
 1165 
Lateral parabrachial nucleus lesions in the rat: aversive and appetitive gustatory 1166 
conditioning 1167 
S Reilly and R Trifunovic (2000) 1168 
Brain Research Bulletin 52(4): 269-278. 1169 
 1170 
Lateral parabrachial nucleus lesions in the rat: neophobia and conditioned taste aversion 1171 
S Reilly and R Trifunovic (2001)  1172 
Brain Research Bulletin 55(3): 359-366. 1173 
 1174 
Efferent connections of the parabrachial nucleus in the rat 1175 
CB Saper and AD Leowy (1980) 1176 
Brain Research 197(2): 291-317. 1177 
 1178 
Branching patterns of parabrachial neurons projecting to the central extended amgydala: 1179 
single axonal reconstructions 1180 
M Sarhan, MJ Freund-Mercier and P Veinante (2005) 1181 
Journal of Comparative Neurology 491(4): 418-42. 1182 
DOI: 10.1002/cne.20697. 1183 
 1184 
Neurophysiologic study of central pain in patients with Parkinson disease 1185 
P Schestatsky, H Kumru, J Valls-Solé, F Valldeoriola, MJ Marti, E Tolosa and ML Chaves (2007) 1186 
Neurology 69(23): 2162-9.  1187 
47 
 
DOI: 10.1212/01.wnl.0000295669.12443.d3. 1188 
 1189 
Interactions between the basal ganglia, the pontine parabrachial region, and the 1190 
trigeminal system in cat 1191 
P Shirvalkar, TL Veuthey, HE Dawes, EF Chang and JS Schneider (1986) 1192 
Neuroscience 19: 411 W425. 1193 
 1194 
Enhanced pain-induced activity of pain processing regions in a case-control study of 1195 
episodic migraine 1196 
TJ Schwedt, CD Chong, CC Chiang, L Baxter, BL Schlaggar and DW Dodick (2014) 1197 
Cephalalgia 34(12): 947-958.  1198 
DOI: 10.1177/0333102414526069. 1199 
 1200 
Subthalamic deep brain stimulation versus best medical therapy for L-dopa responsive 1201 
pain in Parkinson's disease 1202 
O Sürücü, H Baumann-Vogel, M Uhl, LL Imbach and CR Baumann (2013) 1203 
Pain 154(8): 1477-1479. 1204 
DOI: 10.1016/j.pain.2013.03.008 1205 
 1206 
Abnormal processing of the nociceptive input in Parkinson's disease: a study with CO2 1207 
laser evoked potentials 1208 
M Tinazzi, C Del Vesco, G Defazio, E Fincati, N Smania, G Moretto, A Fiaschi, D Le Pera and M 1209 
Valeriani (2008) 1210 
Pain 136(1-2): 117-24.  1211 
DOI: 10.1016/j.pain.2007.06.022. 1212 
 1213 
Direct projections from the deep layers of the superior colliculus to the subthalamic 1214 
nucleus in the rat 1215 
H Tokuno, M Takada, Y Ikai and N Mizuno (1994) 1216 
Brain Research 639: 156-160. 1217 
 1218 
Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives 1219 
48 
 
M de Tommaso, L Arendt-Nielsen, R Defrin, M Kunz, G Pickering and M Valeriani (2016)  1220 
Behavioral Neurology 75762922016.  1221 
DOI: 10.1155/2016/7576292. 1222 
 1223 
 1224 
 1225 
 1226 
 1227 
 1228 
 1229 
 1230 
  1231 
49 
 
FIGURES AND FIGURE LEGENDS  1232 
Figure 1 1233 
 1234 
Figure 1. Summary of the objectives and methods. 1235 
 1236 
 1237 
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Figure 2 1238 
 1239 
Figure 2. Histological and electrophysiological markers of recorded STN neurons -  A.  Location of 1240 
recording sites within the STN. Note that the number of non-responding cells is higher in the caudal 1241 
part of STN. B. Example of triphasic (top) and biphasic (bottom) spike waveforms of STN neurons. C. 1242 
Individual recordings illustrating STN irregular (top), regular (middle) and in burst (bottom) firing 1243 
pattern. Abbreviations: F: nucleus of the fields of Forel; Gem: Gemini hypothalamic nucleus; LH: 1244 
lateral hypothalamic area; PeF: perifornical nucleus; PSTh: parasubthalamic nucleus; Subl: subincertal 1245 
nucleus; Te: terete hypothalamic nucleus; VM: ventromedial thalamic nucleus; VPL: ventral 1246 
posterolateral thalamic nucleus; VPM: ventral posteromedial thalamic nucleus; ZID: zona incerta, 1247 
dorsal part; ZIV: zona incerta, ventral part.  1248 
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Figure 3 1249 
 1250 
Figure 3. STN nociceptive phasic and tonic response  W A. Phasic responses. Peristimulus histograms 1251 
showing individual cases of different types of phasic noxious evoked responses in the STN. The 1252 
dashed vertical line indicates the onset time of the nociceptive footshock. The n associated with each 1253 
histogram indicated the number of cases exhibiting that class of response; total n = 98. B. Tonic 1254 
responses. Peristimulus histograms showing individual cases of decreased (left) and increased (right) 1255 
STN baseline firing rate with the nociceptive stimulation. Histograms of the group mean data (+/- 1256 
sem) during the sham (dark gray) and nociceptive (light gray) stimulation showing a significant 1257 
increase or decrease of the baseline firing rate of the up (p < 0.001) and down group (p < 0.001) and 1258 
no effect of the no change group (p = 0.1272). Note the higher baseline firing rate of the down cells 1259 
during the sham stimulation compared to the up groups (p < 0.05).  1260 
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 1261 
 1262 
Figure 4 1263 
 1264 
 1265 
Figure 4: Plots of the STN lesion - A. Schematic of the ibotenic acid STN lesions, each colour 1266 
represents the plot of an individual animal. B. Coronal sections (stained with cresyl violet) of the STN 1267 
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following a bilateral injection of ibotenic acid. Red arrows indicate the location of the lesion and 1268 
black arrows the tract of the cannula. Scale bars = 400 µm.  1269 
Figure 5 1270 
 1271 
 1272 
 1273 
Figure 5. Effect of local injection of muscimol in PBN on STN nociceptive responses. The set of 1274 
graphs presents raster displays and peri-stimulus histograms of three single cases (A, B and C) aligned 1275 
on the presentation of 120 stimuli (electrical footshocks delivered at 0.5 Hz; vertical red line). Prior to 1276 
the injection of muscimol, both the PBN (a, e, i) and STN (c, g, k) neurons were responsive to the 1277 
footshock. Following the injection of muscimol into the PBN, local neurons became less (b, f) or 1278 
unresponsive to the footshock (j) and so did the STN neurons (d, h, l). Note that PBN blockade with 1279 
muscimol abolished different STN response types such as bipolar +/- (a), mono phasic short/short (g) 1280 
and mono phasic short/long (k). 1281 
 1282 
 1283 
 1284 
 1285 
  1286 
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Figure 6 1287 
 1288 
Figure 6. Effect of SC lesion on STN nociceptive responses - A. Coronal sections (stained with cresyl 1289 
violet) of the SC following a unilateral injection of ibotenic acid (dotted line, left) and its control 1290 
contralateral side (right). Scale bars = 500 µm. B. Schematic of a typical lesion (in gray) with ibotenic 1291 
acid in the SC. C. Plot of STN phasic noxious evoked responses in the STN according to their duration 1292 
and latency in control (white) and SC lesioned (black) animals. The dotted line box highlights the 1293 
absence of long duration responses in SC lesioned rats.  D. Table showing the proportion of STN 1294 
nociceptive response types in control and SC lesioned animals. Note that the proportion of STN long 1295 
lasting responses decreases in SC lesion animals. 1296 
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Figure 7 1297 
 1298 
 1299 
Figure 7. Effect of PBN lesion on STN nociceptive responses - A. Schematic of the ibotenic acid lesion 1300 
of the PBN. Each individual lesion is illustrated in different tone of gray. B. Coronal sections (stained 1301 
with cresyl violet) of the parabrachial nucleus following a unilateral injection of ibotenic acid (dotted 1302 
line, top) and its control contralateral side (bottom). Scale bars = 500 µm. C. Plot of STN phasic 1303 
noxious evoked responses in the STN according to their duration and latency in control (white) and 1304 
PBN lesioned (black) animals. Note that PBN lesion abolished all type of STN nociceptive responses. 1305 
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D. Table showing the proportion of STN nociceptive response types in control and PBN lesioned 1306 
animals.  1307 
Figure 8 1308 
 1309 
 1310 
Figure 8. Anterograde tracer in the PBN  W A. 3D renderings of parasagittal brain sections covering 1311 
the PBN and STN width, illustrating the different bundles leaving the PBN following a local injection 1312 
of an anterograde tracer (PHAL). B. Sagittal sections illustrating a PHAL injection site in the lateral 1313 
PBN (c), associated with labeled terminals in the medial (a) and lateral (b) STN. PBN labeled terminals 1314 
contain dense bouton synaptic mainly localized in STN dorsal sector (d-i). Scale bars: a-c = 200 µm, d-i 1315 
= 20 µm. C. Schematic illustrating the location of terminals and synaptic in the STN following the 1316 
injection of biotinylated dextran amine (BDA) in the lateral portion of the rostral PBN (insert box). 1317 
Abbreviations: IC: inferior colliculus; IS: injection site; PBN: parabrachial nucleus; PPN: 1318 
pedunculopontin nucleus; SC: superior colliculus; SNc: substantia nigra pars compacta; SNr: 1319 
substantia nigra pars reticulate; STN: subthalamic nucleus. 1320 
 1321 
 1322 
 1323 
Figure 9 1324 
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 1325 
Figure 9. Retrograde tracer in the STN  W A. Drawing of coronal sections centered on the ipsilateral 1326 
(left) and contralateral (right) PBN to illustrate the location of the retrogradely labeled cells following 1327 
an injection of a retrograde tracer Fluorogold in the STN. B. Photomicrographs of retrogradely 1328 
labeled neurons in the PBN (a) following the injection of cholera toxin unit B (CTB) in the STN (b). 1329 
Scale bars = 200 µm. C. Morphology of retrogradely labeled PBN neurons following an injection of 1330 
CTB into the STN. Scale bars: 20 µm. 1331 
 1332 
 1333 
 1334 
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 1335 
Abbreviations: cp: cerebral peduncle; IS: injection site; lPBN: lateral parabrachial nucleus; mPBN: 1336 
medial parabrachial nucleus; scp: superior cerebral peduncle; STN: subthalamic nucleus. 1337 
Note: The amplitude of the response is the maximum amplitude during the response and the 1338 
magnitude of the response is the mean number of single- multi-unit events between response onset 1339 
and offset minus the baseline mean. 1340 
TABLE 2: NOCICEPTIVE RESPONSES IN THE SUBTHALAMIC NUCLEUS, SUPERIOR COLLICULUS AND PARABRACHIAL 
NUCLEUS 
 
MICROINJECTION OF MUSCIMOL IN THE SUPERIOR COLLICULUS 
Superior colliculus Subthalamic nucleus 
Pre muscimol Post muscimol Pre muscimol Post muscimol 
Latency ?       9 ± 0.8 ms 7.60 ± 0.68 ms 25.33 ± 5.27 ms 28.38 ± 7.75 ms 
Duration ? 19.62 ± 5.00 ms     14 ± 3.03 ms 176.13 ± 60.37 ms     135.74 ± 50.19 ms * 
Amplitude ? 322.29 ± 58.16 Hz  125.00 ± 26.22 Hz * 15.61 ± 3.29 Hz   14.4 ± 2.44 Hz 
Magnitude ? 140.20 ± 28.01 Hz   45.01 ± 9.16 Hz * 10.21 ± 1.99 Hz   7.24 ± 1.41 Hz 
Baseline FR no footshock ? 18.27 ± 2.19 Hz - 4.37 ± 0.8 Hz - 
ĂƐĞůŝŶĞ&ZĨŽŽƚƐŚŽĐŬ ? 20.79 ± 2.66 Hz     7.69 ± 3.00 Hz *   6.06 ± 1.48 Hz    6.45 ± 1.38 Hz 
 
MICROINJECTION OF MUSCIMOL IN THE PARABRACHIAL NUCLEUS 
Parabrachial nucleus Subthalamic nucleus 
Pre muscimol Post muscimol Pre muscimol Post muscimol 
Latency ?        11.55 ± 1.35 ms 19.00 ± 2.48 ms * 24.54 ± 3.13 ms       18.43 ± 1.73 ms 
Duration ?  26.45.12 ± 3.85 ms       14 ± 3.49 ms *   98.00 ± 27.35 ms      45.75 ± 12.04 ms * 
Amplitude ? 146.97.42 ± 23.66 Hz    83.26 ± 17.02 Hz * 26.98 ± 5.72 Hz   17.18 ± 3.26 Hz * 
Magnitude ?        45.16 ± 7.45 Hz   23.70 ± 4.57 Hz *    10.31 ± 2 Hz     6.65 ± 1.44 Hz * 
Baseline FR no footshock ?        24.25 ± 1.97 Hz -   5.89 ± 0.49 Hz - 
Baseline FR footshock ?        20.55 ± 2.42 Hz 14.15 ± 2.76 Hz   5.50 ± 0.71 Hz          5.39 ± 0.57 Hz 
Mean ± SEM - * statistically different from pre muscimol measure 
59 
 
Figure 10  ? Supplementary results 1341 
Figure 10  - Noxious footshock  W A. Histogram showing the increase of the number of responding 1342 
cells with the increase of the footshock intensity. B. Increase of the maximum amplitude and 1343 
magnitude of phasic nociceptive evoked responses with the increase of the footshock intensity. C. 1344 
Individual example of an STN cell excited both by a mechanical noxious stimulation (pinch  W left) and 1345 
a 5 mA noxious footshock (right). D. Coronal sections of the lumbar region of the spinal cord 1346 
processed for c-fos expression in an animal subjected to 1 h unilateral noxious electrical stimulation 1347 
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of the hindpaw (left) and in a control animal in which the electrodes were implanted into the 1348 
hindpaw, but no footshock applied. 1349 
